tive prognostic microenvironmental components (CD68-, PD-1-and granzyme B-positive cells) was of independent prognostic significance (p = 0.002). Conclusion: Increased numbers of CD68-positive tumor macrophages indicate an adverse overall outcome in HL.
Introduction
Classical Hodgkin lymphoma (cHL) is a lymphoid neoplasm consisting of mononuclear Hodgkin and multinuclear Reed-Sternberg cells (HRSC) embedded in a nonneoplastic background infiltrate of small lymphocytes, eosinophilic and neutrophilic granulocytes, histiocytes, plasma cells, fibroblasts and collagen fibers [1] . It is the paradigm of a formerly lethal neoplastic disease that became curable with the introduction of modern multimodal therapies in the 1970s. With risk-and response-adapted multimodal therapy, over 85% of cHL patients achieve a long-lasting and complete remission [2] . Nevertheless, about 3% of stage I and II and about 7% of stage III and IV cases present with refractory disease, and another 10-15% relapse, requiring more intensive treatments [3] . A drawback of the impressive achievements in cHL treatment is the increasing late toxicity, particularly the high incidence of secondary malignancies, such as therapy-related myeloid neoplasms, breast and lung cancer and car-diovascular diseases [4] . Thus, it is important to be able to predict/identify patients who are treatment resistant and/ or have a higher risk of relapse and find alternative therapeutic options. In addition, patients who might be overtreated by the current treatment regimens must be identified to reduce treatment-associated toxicity.
Prior to the introduction of modern therapy protocols, histological type and nodular sclerosis grading were predictive for disease-specific outcome in cHL [5] [6] [7] [8] . Today, disease stage, presence of B symptoms, patient clinical history, including risk factors such as coincidental HIV infection, and laboratory parameters are the most important predictive factors [9, 10] . Studies searching for a meaningful HRSC-related phenotypic prognostic biomarker in cHL are contradictory and poorly reproducible [1, 11, 12] . Contrary to HRSC-related biomarkers, reactive cellular environment characteristics seem to be of greater prognostic significance in cHL [13] [14] [15] [16] [17] [18] [19] . Importantly, cHL lymphomagenesis is more closely related to the cellular background infiltrate than in other lymphomas. HRSC produce many cytokines and chemokines, resulting in the influx and activation of CD4+ cells and histiocytes; conversely, HRSC respond to the chemokines and growth factors produced by these surrounding cells, the latter providing essential feedback signals to stimulate proliferation and inhibit apoptosis in HRSC [20, 21] . A possible prognostic role of macrophages and histiocytes in cHL was suggested decades ago [22] [23] [24] . A recent gene expression profiling study on an unselected cHL collective with subsequent immunohistochemical verification on a collective enriched for treatment failures showed an important correlation between the number of CD68-positive macrophages and adverse disease-specific survival (DSS) and worse outcome after secondary high-intensity therapy with autologous stem cell support, but results have thus far not been validated in an independent collective [25] . Therefore, we systematically analyzed the prognostic importance of the number of CD68-positive macrophages in an unselected series of 105 clinically and histopathologically well-characterized cHLs in tissue microarrays (TMAs).
Materials and Methods
We used a patient set of our previously reported TMA collective [19, 26] that met the following criteria: complete clinical documentation, presence of at least 5 unequivocal HRSC/case on the examined slides and presence of at least 1 CD68-positive cell/case on the examined slides. Only 105 of the initial 259 cases could be considered based on these criteria.
Patients cHL cases (n = 105) diagnosed between 1974 and 2000 and reclassified according to the World Health Organization 2008 criteria were collected from the archives of the Institutes of Pathology at the University Hospitals of Basel, Switzerland, and Innsbruck, Austria. Paraffin blocks were selected based on availabil ity and preservation. Clinical and follow-up data (summarized in table 1) were obtained from chart reviews. Retrieval of tissue and clinical data was performed according to the regulations of the local institutional review boards and data safety laws. Treatment was either standard or consistent with the investigational protocols active during the time the patients were diagnosed. Patients were staged surgically as stage I or II when radiotherapy (RT) was administered as the sole treatment. Otherwise, patients were staged clinically and treated with risk-adapted treatment strategies according to the protocols of the German Hodgkin Study Group valid at the time of diagnosis. In advanced stages, RT was applied for treatment of residual disease or primary bulky disease [27, 28] . Disease remission was defined as absence of disease for at least 1 month as determined by laboratory and imaging studies as well as physical examination. Disease relapse was defined as disease progression occurring at least 1 month after achieving disease remission. Treatment failure was defined as disease relapse or primary treatment resistance; the latter was not observed in the present collective. Overall survival (OS) was defined as the time from initial diagnosis to death or the last follow-up examination or other patient contact. DSS was defined as the time from initial diagnosis to death from lymphoma or the last follow-up examination or other patient contact. Relapse-free survival (RFS) was defined as the time from initial diagnosis to disease relapse or the last follow-up examination or other patient contact without imaging, clinical or anamnestic evidence of disease recurrence.
TMA Construction
The TMAs were constructed and validated as described elsewhere [19, 26] . Two cores from every sample were arrayed. The construction of the TMAs was approved by the institutional review boards of the participating centers at the time of case submission, and cases have been kept anonymous to meet the legal and ethical requirements for their use in the present study.
Immunohistochemical Evaluation
The slides were immunohistochemically stained for CD68 using an automated immunostainer (Nexes, Ventana, USA), utilizing the PGM1 antibody from Dako (M0876; 1: 200; antigen retrieval with citrate buffer, pH 6, in a microwave oven at 100 ° C for 15 min). The total number of cells and CD68-stained cells on each array spot was counted at ! 200 magnification. The percentage of CD68-positive cells for each spot was subsequently extracted. The mean percentage over both spots, provided that both contained HRSC, was considered for final statistical analysis, except for cases in which the difference between both spots exceeded 1% or would lead to reclassification of a case as either negative or positive when considering the cutoff score for CD68-positive tumor macrophages. In both of the latter instances, the HRSC-richer array spot was further considered (see Results). Details on FOXP3, granzyme B and PD-1 staining have been reported previously [18, 19] . To assess the reproducibility of the CD68 data, comparison between the results of two observers (A.T. and M.S.M.) in one third of the cases was performed in a blinded fashion and assessed using interclass correlation coefficients.
Statistics
Statistical analysis, including data description, was performed using the Statistical Package of Social Sciences 15.0 software (Chicago, Ill., USA). The degree of agreement between observers was evaluated by interclass correlation coefficients, using Cronbach's alpha reliability analysis, with alpha 1 0.75 indicating very good reproducibility. Spearman rank correlation coefficients were used to analyze relationships between markers and/or clinical variables. The Mann-Whitney U and Kruskal-Wallis tests were applied, where appropriate, to assess mean differences between groups. The prognostic performance of the variables and determination of optimal cutoff values of continuous variables were established by receiver operating characteristic (ROC) curves plotting sensitivity versus 1 -specificity. The optimal cutoff point was calculated using Youden's index (Y), where Y = sensitivity + specificity -1, since this method can be applied when there is no particular requirement for sensitivity and/or specificity [29] . ROC analysis was applied for OS, DSS and RFS. Survival was then analyzed by the Kaplan-Meier method applying the cutoff values calculated by ROC/Y. Survival results from the present study as well as prognostic factors already established in the study collective [18, 19] , for which the ROC or Kaplan-Meier methods suggested statistical (p ! 0.05) or borderline significance (p ! 0.1), were further considered in the multivariate analysis using a Cox regression model.
Results

Patients
Within the median follow-up period of 142 months, 72% of the patients survived, 10% died from lymphoma and 18% died from other causes such as second malignancies (n = 11), cardiovascular events (n = 6), infections (n = 2) and trauma (n = 1), the former 3 being highly probably attributable to lymphoma therapy. Mean OS was 243 months [95% confidence interval (CI) 218-268], and mean DSS was 297 months (95% CI 278-318). The average time to first relapse was 56 months (range 7-240). For the prognostic significance of basic clinicopathological variables, see table 1 .
Assessment of CD68-Positive Tumor Macrophages
Immunohistochemistry is shown in figure 1 . Cronbach's alpha for interobserver reproducibility for a given case was 0.829. Cronbach's alpha for agreement between results assessed on both TMA spots of a given case was 0.802. Cases in which the difference between both spots/ cores exceeded 1% or would have led to reclassification of a case as either negative or positive when considering the cutoff score for CD68-positive tumor macrophages (n = 26 ) were reanalyzed on a double-headed microscope by both investigators. The different distribution of CD68-positive tumor macrophages could be reproduced after reevaluation in all these cases and was attributable to the absence or paucity of HRSC on either the first or second arrayed spot. Importantly, in these cases, specific consideration of the prognostic value of the number of CD68-positive tumor macrophages assessed on either the first or the second arrayed spot showed that only the number assessed on the spot containing HRSC or enriched in HRSC was of prognostic importance. In such equivocal cases, results assessed on the HRSC-richer array spot were considered further. For descriptive results, see table 2 . [18, 19] . The respective ROC curves considering OS are shown in figure 2 . With respect to OS, the area under the ROC curve for CD68-positive macrophages was 0.660 (95% CI 0.514-0.806), indicating that consideration of CD68-positive macrophage numbers is a significant improvement over a random guess. The Y value pointed to 1 0.82% CD68-positive tumor macrophages as being the most relevant cutoff score with respect to OS, with a prognostic sensitivity of 74% and a specificity of 65%. Applying this cutoff score, Kaplan-Meier analysis showed worse OS for cHL with increased numbers of CD68-positive tumor macrophages (mean 185 months, 95% CI 142-227, median 192 months) compared to cases with lower numbers (mean 285 months, 95% CI 259-311, median not reached). Eleven of 62 patients with ^ 0.82% CD68-positive tumor macrophages died, compared to 19 of 43 with 1 0.82% CD68-positive tumor macrophages (p ! 0.001; fig. 3 ). There were significant differences with regard to the causes of death between cases with in- creased and decreased tumor macrophages, with a particular accumulation of second malignancies and infections among those patients with increased tumor macrophages ( table 3 ) . Rounding up of the cutoff score from ^ 0.82 to ^ 1%, which we assumed to represent a more practicable cutoff score, would have reclassified 3 of the studied cases from the prognostically adverse to the prognostically favorable group. Since 2 of these patients died from their disease, ROC analysis indicated that application of such a cutoff score rather than ^ 0.82% to our collective would lead to a drop in prognostic sensitivity to 63% without increasing the specificity. Thus, though we acknowledge that a cut-off score of 1% is more practical, for the purposes of our study, we strictly adhered to the ^ 0.82% cutoff, as suggested by ROC/Y. Application of the cutoffs suggested by Steidl et al. [25] , i.e. 0 to ! 5%, 5-25% and 1 25%, led to analogous results, but the absolute number of the collective with a CD68-positive cell number over the cutoff was smaller; thus, the prognostic specificity of adverse events for a cutoff of 6 5% CD68-positive tumor macrophages rose to 92%, but the sensitivity dropped to 16%. In our collective, which was not specifically enriched for treatment failures, we did not observe a single case with 1 9% CD68-positive tumor macrophages. When analyzed in subgroups according to the clinicopathological variables listed in table 1 , the negative prognostic effect of an increased number of CD68-positive tumor macrophages retained its significance for both genders (males p = 0.008, females p = 0.015), patients younger than 55 years (p = 0.046), stage II (p = 0.001) and III disease (p = 0.09), patients with and without B symptoms (p = 0.016 and 0.013, respectively), cHL of the mixed cellularity subtype (p = 0.008), cHL without Epstein-Barr virus association (p ! 0.001) and patients treated only with chemotherapy (p = 0.002), especially those treated with cyclophosphamide, vincristine, procarbazine and prednisone (COPP; p = 0.001), and was less pronounced, in patients treated with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD; p = 0.079) and with COPP plus RT (p = 0.019). However, the shape of the respective Kaplan-Meier curves also suggested a negative prognostic effect of an increased number of CD68-positive tumor macrophages in the subgroups in which statistical significance was not reached. Importantly, the prognostic effects of CD68-, PD-1-and granzyme B-positive cellular contents were cumulative ( fig. 4 ) . In a multivariable analysis considering patient age, disease stage and numbers of FOXP3-, granzyme B-and PD-1-postive tumor-infiltrating lymphocytes, only age, in particular 6 55 years, appeared to be of independent prognostic significance for OS (p = 0.046). A combination background score considering all prognostically negative microenvironmental components, i.e. CD68-, PD-1-and granzyme B-positive cell numbers, was of independent prognostic significance (p = 0.002; relative risk 2.63, 95% CI 1.41-4.93) compared to age (p = not significant; relative risk 2.07) and disease stage (p = not significant; relative risk 1.31). Adding CD68 to PD1 and granzyme B made it possible to identify a subgroup of cHLs with an excellent prognosis if all cellular micromilieu components were decreased (1 death with/from lymphoma out of 20 patients) as well as a group with a dismal prognosis if all components were increased (2 deaths with/from lymphoma and 6 deaths from a second malignancy out of 11 patients).
Discussion
Steidl et al. [25] recently reported that increased CD68-positive tumor macrophage numbers have a major impact on the prognosis of cHL. Here, we present the first study to address the reproducibility of their findings. We were able to principally confirm the data of Steidl et al. [25] as well as the findings of Ree and Kadin [23] , reported 25 years ago, in our collective, which was not specifically enriched for treatment failures. This lack of enrichment for treatment failures as well as the application of the more specific PGM1 anti-CD68 antibody instead of the KP1 antibody, as applied by Steidl et al. [25] , might be the primary reasons for the slightly lower CD68-positive tumor macrophage numbers observed in our collective. In addition, we refined the role of this single biomarker in the context of the cellular micromilieu of cHL. We observed an adverse prognostic significance of an increased number of CD68-positive tumor macrophages with respect to OS. This effect was particularly pronounced in 
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Color version available online mixed cellularity cases, in patients younger than 55 years, in stage II and III disease and in cases without EpsteinBarr virus association. With regard to treatment, especially patients treated by COPP-based therapy, either with or without RT, as well as those treated by chemotherapy alone (either COPP or ABVD), without RT, there was a negative prognostic effect of CD68-positive cell numbers. The advantages of our study are as follows: (1) no preselection of the cases, in particular no enrichment for treatment failures; (2) very long follow-up period (median 12 years); (3) ROC curve-based determination of prognostic cutoff values with both maximum specificity and sensitivity without the need for arbitrary cutoff scores; (4) extensive previous phenotypic cellular background and HRSC characterization of the studied collective [18, 19, 26, 30] , and (5) distribution of cHL subtypes reflecting that of the general population.
On the other hand, the limitations of our study include the following: (1) this was a retrospective study with a long period of sample collection that could include possible bias due to different treatments applied within this period and (2) lack of data on International Prognostic Score and secondary treatment. Importantly, the first and the last point among the advantages as well as the first point among the disadvantages might explain why a prognostic effect with regard to DSS and RFS was not observable in our collective compared to that of Steidl et al. [25] , the latter being enriched for treatment failures with a particularly low number of mixed cellularity cases.
Beyond the general reproduction of the results of Steidl et al. [25] , the new findings of our study are: (1) discovery in a general cHL collective of a cutoff score of 0.82% (for practical purposes 1%) CD68-positive tumor macrophages for OS prognostication, suggesting that at diagnostic determination the histopathologist should recognize whether on average every 100th cell from the cellular background represents a CD68-positive macrophage; (2) CD68-positive cellular contents are prognostically relevant only if assessed in HRSC-containing or -enriched areas (hot spots) rather than in whole tissue specimens; (3) CD68-positive tumor macrophage numbers correlate with a cellular background (low FOXP3/high granzyme B and PD-1 cellular background) that is usually associated with an unfavorable outcome in cHL [16] [17] [18] [19] 30] , and (4) a particular association of increased CD68-positive tumor macrophage numbers at diagnosis with deaths from second malignancies and infections. Other significant correlations include that between CD68-positive tumor macrophage numbers and patient age in cHL, as well as overrepresentation of cHLs with mixed cellularity and lymphocyte depletion in cases with increased CD68-positive macrophages, which is in agreement with observations from more than 2 decades ago [23] .
The reason for the observed prognostic significance of CD68-positive tumor macrophage contents with regard to cHL outcome are unknown, but it probably reflects a particular inflammatory tumor microenvironment or individual immunologic or immunogenetic imprinting [31] . Direct effects of the respective cellular components can also be assumed. For example, it has been suggested that tumors may use the power of granzyme B-positive lymphocytes to their advantage, because mice lacking granzyme B clear tumor grafts more efficiently than do wild-type mice [32] . At least in our collective, CD68-positive tumor macrophage numbers were not an independent prognostic factor in cHL compared to age, disease stage and numbers of FOXP3-, granzyme B-and PD-1-positive tumor-infiltrating lymphocytes. When considered together with other microenvironmental components, namely granzyme-B-and PD-1-positive cells, CD68-positive cells considerably increased the specificity and sensitivity of prognosis in cHL independent of patient age or disease stage being a particular indicator of an increased risk for patients to die of a second malignancy or infection. This supports our assumption that CD68-positive tumor macrophages represent an important, but not exclusive, 'player' in the unfavorable microenvironmental signature probably composed of a limited number of other cytotoxic and regulatory immune cells, the puzzling roles of which remain to be elucidated.
To summarize, increased numbers of CD68-positive tumor macrophages indicate an adverse overall outcome in cHL. For the purpose of prognostication, CD68-positive cell numbers should be assessed in HRSC-rich cHL areas. Increased CD68-positive tumor macrophage counts correlate with a cellular background (low FOXP3/ high granzyme B and PD-1 cells) that is usually associated with an unfavorable outcome in cHL. Prospective studies on cHL collectives treated with modern modalities without selection bias are needed to establish the prognostic importance of the different microenvironmental components.
